Cited by 370Sexual Differentiation and DisordersAdrenal Hormones and DisordersMetabolism and Genetic Disorders

Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: Implications for genetic diagnosis and association with disease manifestation

Wedell, A.·1994·Journal of Clinical Endocrinology & Metabolism

Abstract

We have characterized the disease-causing mutations in the steroid 21-hydroxylase genes of 127 patients with different clinical forms of congenital adrenal hyperplasia, representing 186 unrelated chromosomes. The gene was completely absent on 29.8% of the chromosomes, and this together with the I2 splice (27.7%), I173N (20.8%), V282L (5.4%), and R357W (3.8%) mutations constitute 87.5% of all affected chromosomes. In total, 15 different sequence aberrations combine to form 19 different disease-causing alleles. The results confirm that genotyping is an efficient means of diagnosing steroid 21-hydroxylase deficiency, although special consideration is needed to resolve genotypes when full families are not available. Clinical presentations of the different combinations of mutations indicate that genotyping is reliable for prediction of clinical outcome in patients with 21-hydroxylase deficiency. It is especially helpful in determining whether in utero treatment of affected females is indicated and in classifying the severity of 21-hydroxylase deficiency in children diagnosed through neonatal screening, before symptoms have appeared.

Integrity signals

Registry

Crossref · 10.1210/jc.78.5.1145

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Functional in vitro studies classify CYP21A2 pathogenic variants into four groups based on residual enzymatic activity: group 0 (null, 0%), group A (<2%), group B (3-7%), and group C (20-60%).

    “Functional in vitro studies have allowed classification of CYP21A2 pathogenic variants into four groups based on residual enzymatic activity: group 0 (null, 0%), group A (<2%), group B (3-7%), and group C (20-60%), as summarized in Table 1 (18, 31, 48–50).”
  • In European and North American populations, large gene deletions and CYP21A1P/CYP21A2 chimeric conversions, predominantly associated with salt-wasting phenotypes, constitute 20-30% of pathogenic alleles.

    “In European and North American population, where long-standing newborn screening programs facilitate early detection, large gene deletions and CYP21A1P/CYP21A2 chimeric conversions, predominantly associated with SW phenotypes, constitute 20-30% of pathogenic alleles (25, 28, 30, 31).”
  • In most populations, targeted genotyping methods achieve a detection rate of approximately 90-95% of known pathogenic alleles.

    “In most populations, these methods achieve a detection rate of approximately 90-95% of known pathogenic alleles, providing a balance between analytical precision, efficiency and reproducibility, making it suitable for detecting recurrent CYP21A2 variants in diagnostic laboratories during the 1990s and early 2000s (27, 31, 47, 71, 72).”
  • CAH-X is associated with joint hypermobility, chronic arthralgia, joint subluxations, hernias, and cardiac defects.

    “CAH-X is associated with joint hypermobility, chronic arthralgia, joint subluxations, hernias, and cardiac defects (193,194).”
  • Genotype consistently predicts phenotype in very severe and very mild cases of 21-hydroxylase deficiency.

    “It is clear that genotype consistently predicts phenotype in very severe and very mild cases of 21-hydroxylase deficiency (361, 362).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wedell, A.
Affiliations
Karolinska University Hospital (SE)
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1994-05-01
Volume
78
Issue
5
Pages
1145-1152
ISSN
0021-972X (ISSN-L)
OpenAlex
W2077894644
Cited by
370
References
8
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 5 · 2020: 10 · 2019: 12 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 12 · 2013: 14 · 2012: 11
FWCI
3.29
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
21-hydroxylase, CYP21, congenital adrenal hyperplasia, 21-hydroxylase deficiency, mutation spectrum, pathogenic variants, genotype-phenotype correlation, genotyping, in utero treatment, newborn screening, disease severity classification, Sweden
MeSH terms
Adrenal Hyperplasia, Congenital, Alleles, Female, Genotype, Humans, Male, Mutation, Phenotype, Steroid 21-Hydroxylase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review